MBRX Moleculin Biotech, Inc.
Moleculin Biotech, Inc. (MBRX) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.83 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +2.0% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.
Sector
Healthcare
Industry
Biotechnology